ClinicalTrials.gg
TerminatedNCT04338061Updated Mar 21, 2025Results posted

Study of Evobrutinib in Participants With RMS (evolutionRMS 2)

A Phase 3 interventional study of Teriflunomide and Evobrutinib in Relapsing Multiple Sclerosis, sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. Terminated at 278 sites in 32 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-03-21.

Sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 3, Interventional, and Treatment

Why this study was terminated
Primary analysis of the RMS phase 3 study (MS200527_0082) resulted in the early termination of the study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,166
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany — none open to participants now, 1 under way, none of them phase 3. Multiple Sclerosis · Merck KGaA, Darmstadt, Germany.

Enrollment
Largest of 33
1,166 · median 219
Started
2020
with 1 other
Phase 3
11 of 71
none open now
Registered
63rd of 71
by date

Among the 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany, this one has the largest enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2020, is one of 11 in phase 3, and was the 63rd registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

None of the 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany is open now. The open studies under Multiple Sclerosis, anywhere →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany as a file.
02

Study summary

The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio®), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS). Participants who complete the double-blind treatment period (DBTP) and double-blind extension period (DBEP) prior to approval of a separate long-term follow-up study in their country will get an option for evobrutinib treatment continuation through a 96-week open-label extension (OLE) period.

03

Conditions studied

  • Relapsing Multiple Sclerosis

Browse trials for

Keywords

  • Evobrutinib
  • Teriflunomide
  • Aubagio®
  • Relapsing Multiple Sclerosis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are diagnosed with RMS (relapsing-remitting multiple sclerosis [RRMS] or secondary progressive multiple sclerosis [SPMS] with relapses) in accordance with 2017 Revised McDonald criteria (Thompson 2018)
  • Participants with one or more documented relapses within the 2 years before Screening with either: a. one relapse which occurred within the last year prior to randomization, OR b. the presence of at least 1 gadolinium-enhancing (Gd+) T1 lesion within 6 months prior to randomization
  • Participants have Expanded Disability Status Scale (EDSS) score of 0 to 5.5 at Screening and Baseline (Day 1). Participants with an EDSS score less than or equal to [\<=] 2 at Screening and Baseline (Day 1) are only eligible for participation if their disease duration (time since onset of symptoms) is no more than 10 years
  • Participants are neurologically stable for >= 30 days prior to both screening and baseline (Day 1)
  • Female participants must be neither pregnant nor breast-feeding or must lack (as defined by either: or surgically sterile), or use an effective method of for the duration of the study and at least 2 years after study intervention due to the long elimination period for teriflunomide of 2 years, unless the participant undergoes an accelerated elimination procedure
  • Male participants must refrain from donating sperm and/or abstain from intercourse with women of child-bearing potential or use an effective method of contraception for the duration of the study and at least 2 years after study intervention due to the long elimination period for teriflunomide of 2 years, unless the participant undergoes an accelerated elimination procedure
  • Participants have given written prior to any study-related procedure
  • Other protocol defined inclusion criteria could apply.

Exclusion criteria

Exclusion Criteria:

  • Participants diagnosed with Progressive MS, in accordance with the 2017 Revised McDonald criteria as follows: a). Participants with Primary Progressive MS. b) Participants with secondary progressive MS without evidence of relapse
  • Disease duration more than (>) 10 years in participants with an EDSS =\< 2.0 at screening and Baseline (Day 1)
  • Immunologic disorder other than MS, or any other condition requiring oral, intravenous (IV), intramuscular, or intra-articular therapy, with the exception of well-controlled Type 2 diabetes mellitus or well controlled thyroid disease
  • Other protocol defined exclusion criteria could apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,166 participants (actual)

Study arms

  • Active comparator
    Teriflunomide

    Drug: Teriflunomide

  • Experimental
    Evobrutinib

    Drug: Evobrutinib

Interventions

  • Participants received Teriflunomide at a dose of 14 milligrams (mg) orally once daily up to 156 weeks in Double blind treatment period (DBTP) followed by once daily oral doses of Teriflunomide 14 mg up to 96 weeks in double blind extension (DBE) period.

  • Participants received Evobrutinib at a dose of 45 mg orally twice daily up to 156 weeks in Double blind treatment period (DBTP) followed by twice daily oral doses of Evobrutinib 45 mg up to 96 weeks in double blind extension (DBE) period.

    Also known as: M2951

06

What researchers measure

Primary outcomes

  1. Double Blind Treatment Period (DBTP) and Double Blind Extension (DBE) Period: Annualized Relapse Rate (ARR)

    The qualifying relapse is the occurrence of new or worsening neurological symptoms attributable to Multiple Sclerosis (MS) (for more than \[\>\] 24 hours, no fever, infection, injury, adverse events (AEs), and preceded by a stable or improving neurological state for more than or equal to \[\>=\] 30 days).

    Time frame: Baseline up to 170 weeks

Secondary outcomes

  1. DBTP and DBE Period: Percentage of Participants Without 12-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)

    Disability progression was defined as increase in EDSS of greater than or equal to \[\>=\] 1 point from baseline EDSS score, if EDSS score at baseline is 5.0 or less and an increase of \>=0.5 point, if the baseline score is 5.5. Disability progression is considered sustained for 12 weeks when the initial increase in the EDSS is confirmed at a regularly scheduled visit at least 12 weeks after the initial documentation of neurological worsening. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). Kaplan-Meier method was used to estimate the percentage of participants without 12-week CDP.

    Time frame: Week 96 and Week 156 (combined DBTP and DBE periods)

  2. DBTP and DBE Period: Percentage of Participants Without 24-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)

    Disability progression was defined as increase in EDSS of greater than or equal to \[\>=\] 1 point from baseline EDSS score, if EDSS score at baseline is 5.0 or less and an increase of \>=0.5 point, if the baseline score is 5.5. Disability progression is considered sustained for 24 weeks when the initial increase in the EDSS is confirmed at a regularly scheduled visit at least 24 weeks after the initial documentation of neurological worsening. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). Kaplan-Meier method was used to estimate the percentage of participants without 24-week CDP.

    Time frame: Week 96 and Week 156 (combined DBTP and DBE periods)

  3. DBTP and DBE Period: Percentage of Participants With 24-Week Confirmed Disability Improvement (CDI) as Measured by Expanded Disability Status Scale (EDSS)

    Disability improvement was defined as a reduction of 1 point from Baseline EDSS score when the Baseline score is \>= 2 and less than or equal to \[\<=\] 6 and a reduction of 0.5 point from Baseline EDSS score when the Baseline score is \>= 6.5 and \<= 9.5. Disability improvement is considered sustained when the initial reduction in the EDSS score is confirmed at a regularly scheduled visit at least 24 weeks after the initial reduction. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). Kaplan-Meier method was used to estimate the percentage of participants with 12-week CDI.

    Time frame: Week 96 and Week 156 (combined DBTP and DBE periods)

  4. DBTP and DBE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) Score at Week 48, Week 96, Week 120, Week 144 and Week 156

    Physical function was assessed with PROMISnq Short Form v2.0 - Physical Function - Multiple Sclerosis 15a (PROMISnq PF(MS) 15a). PROMISnq PF(MS) 15a assesses a participant's abilities and limitations with respect to everyday physical activities. Results are reported as a T-score. In the general population, T-scores have a mean of 50, standard deviation of 10, and range from 10 to 65. Higher T-scores represent higher physical function. Change from baseline in PROMIS PF score was analyzed using Mixed Effect Model for Repeated Measures (MMRM) to evaluate the result of the 2 periods (DBTP and DBE).

    Time frame: Baseline, Week 48, Week 96, Week 120, Week 144 and Week 156 (Combined DBTP and DBE periods)

  5. DBTP and DBE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Score at Week 48, Week 96, Week 120, Week 144 and Week 156

    PROMIS Fatigue score was assessed with PROMIS Short Form v1.0 - Fatigue - Multiple Sclerosis 8a (PROMIS Fatigue (MS) 8a). PROMIS Fatigue (MS) 8a assesses level of fatigue and its interference on daily activities. Results are reported as a T-score. In the general population, T-scores have a mean of 50, standard deviation of 10, and range from 33 to 85. Higher T-scores represent higher fatigue. Change from baseline in PROMIS fatigue score was analyzed using Mixed Effect Model for Repeated Measures (MMRM) to evaluate the result of the 2 periods (DBTP and DBE).

    Time frame: Baseline, Week 48, Week 96, Week 120, Week 144 and Week 156 ((combined DBTP and DBE periods)

  6. DBTP and DBE Period: Total Number of T1 Gadolinium-positive (Gd+) Lesions

    Analysis of Gadolinium-positive T1 lesions was done using magnetic resonance imaging (MRI) scans.

    Time frame: Baseline up to 170 weeks

  7. DBTP and DBE Period: New or Enlarging T2 Lesions Rate

    Analysis of new or enlarging T2 lesions rate was done using magnetic resonance imaging (MRI) scans. Negative binomial model for lesion count (summed over scans) includes treatment and covariates based on randomization strata and baseline volume of T2 lesion (continuous), with offset equal to the log of the time in years between the last available MRI scan and the baseline scan.

    Time frame: Baseline up to 170 weeks

  8. DBTP Period: Neurofilament Light Chain (NfL) Concentration at Week 12

    NfL is a biomarker of neuro-axonal damage whose concentration was assessed in blood at Week 12.

    Time frame: Week 12

  9. DBTP and DBE Periods: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESIs)

    Adverse event (AE): Any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the study drug. Serious AE: an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs: those AEs with an onset date on or after the date of first study intervention administration, or AEs present prior to any study intervention administration but exacerbating after. TEAEs included both Serious TEAEs and non-serious TEAEs. AESIs included liver AEs (possible drug-induced, non-infectious, non-alcoholic, and immune-mediated), infections (serious and opportunistic infections), lipase and amylase elevation, and seizure.

    Time frame: Baseline up to 170 weeks

  10. DBTP and DBE Periods: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity

    Severity of adverse events (AE) were assessed by the investigator per the National Cancer Institute- Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0. Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death. Number of participants with Grades 1, 2, 3, 4 and 5 were reported.

    Time frame: Baseline up to 170 weeks

  11. DBTP and DBE Periods: Change From Baseline in Vital Signs: Diastolic Blood Pressure and Systolic Blood Pressure

    Diastolic blood pressure and systolic blood pressure were measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: diastolic blood pressure and systolic blood pressure from baseline up to 170 weeks were reported.

    Time frame: Baseline up to 170 weeks

  12. DBTP and DBE Periods: Change From Baseline in Vital Signs: Pulse Rate

    Pulse rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: pulse rate from baseline up to 170 weeks was reported.

    Time frame: Baseline up to 170 weeks

  13. DBTP and DBE Periods: Change From Baseline in Vital Signs: Respiratory Rate

    Respiratory rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: respiratory rate from baseline up to 170 weeks was reported.

    Time frame: Baseline up to 170 weeks

  14. DBTP and DBE Periods: Change From Baseline in Vital Signs: Weight

    Changes in vital signs: weight from baseline up to 170 weeks was reported.

    Time frame: Baseline up to 170 weeks

  15. DBTP and DBE Periods: Change From Baseline in Vital Signs: Temperature

    Temperature was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: Temperature from baseline up to 170 weeks was reported.

    Time frame: Baseline up to 170 weeks

  16. DBTP and DBE Periods: Change From Baseline in Electrocardiograms (ECGs): Heart Rate

    Heart rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: heart rate from baseline up to 170 weeks was reported.

    Time frame: Baseline up to 170 weeks

  17. DBTP and DBE Periods: Change From Baseline in Electrocardiograms (ECGs): QT Interval - Fridericia's Correction Formula, PR Interval and QRS Duration

    QT Interval - Fridericia's Correction Formula, PR Interval and QRS Duration was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: QT Interval - Fridericia's Correction Formula, PR Interval and QRS Duration from baseline up to 170 weeks were reported.

    Time frame: Baseline up to 170 weeks

  18. DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Hemoglobin and Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameters: erythrocytes mean corpuscular HGB concentration and hemoglobin. Changes in hematology parameters: erythrocytes mean corpuscular HGB concentration and hemoglobin from baseline up to 170 weeks were reported.

    Time frame: Baseline up to 170 weeks

  19. DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes and Reticulocytes

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameters: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes and Reticulocytes. Changes in hematology parameters: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes and Reticulocytes from baseline up to 170 weeks were reported.

    Time frame: Baseline up to 170 weeks

  20. DBTP and DBE Periods: Change From Baseline in Hematology Parameters: Hematocrit

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Hematocrit. Changes in hematology parameter: Hematocrit from baseline up to 170 weeks was reported.

    Time frame: Baseline up to 170 weeks

  21. DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin. Changes in hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin from baseline up to 170 weeks was reported.

    Time frame: Baseline up to 170 weeks

  22. DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Erythrocytes Mean Corpuscular Volume. Changes in hematology parameter: Erythrocytes Mean Corpuscular Volume from baseline up to 170 weeks was reported.

    Time frame: Baseline up to 170 weeks

  23. DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Bilirubin and Creatinine

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Bilirubin and Creatinine. Changes in biochemistry parameters: Bilirubin and Creatinine from baseline up to 170 weeks were reported.

    Time frame: Baseline up to 170 weeks

  24. DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase. Changes in biochemistry parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase from baseline up to 170 weeks were reported.

    Time frame: Baseline up to 170 weeks

  25. DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Sodium, Potassium, Calcium, Magnesium, Glucose, Chloride, Urea Nitrogen, Phosphate, Bicarbonate and Corrected Calcium

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Sodium, Potassium, Calcium, Magnesium, Glucose, Chloride, Urea Nitrogen, Phosphate, Bicarbonate and Corrected Calcium. Changes in biochemistry parameters: Sodium, Potassium, Calcium, Magnesium, Glucose, Chloride, Urea Nitrogen, Phosphate, Bicarbonate and Corrected Calcium from baseline up to 170 weeks were reported.

    Time frame: Baseline up to 170 weeks

  26. DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Total Protein and Albumin

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Total Protein and Albumin. Changes in biochemistry parameters: Total Protein and Albumin from baseline up to 170 weeks were reported.

    Time frame: Baseline up to 170 weeks

  27. DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Glomerular Filtration Rate

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameter: Glomerular Filtration Rate. Changes in biochemistry parameter: Glomerular Filtration Rate from baseline up to 170 weeks were reported. The Glomerular Filtration Rate was measured as milliliter per minute per 1.73 square meter (mL/min/1.73m\^2).

    Time frame: Baseline up to 170 weeks

  28. DBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Potential of Hydrogen (pH) of Urine

    Urine samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the urinalyses parameter: pH. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Changes in urinalyses parameter: pH from baseline up to 170 weeks was reported.

    Time frame: Baseline up to 170 weeks

  29. DBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Specific Gravity of Urine

    Urine samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the urinalyses parameter: Specific Gravity of Urine. Changes in urinalyses parameter: Specific Gravity of Urine from baseline up to 170 weeks was reported.

    Time frame: Baseline up to 170 weeks

  30. DBTP and DBE Periods: Absolute Concentrations of Immunoglobulin (Ig) Levels

    Absolute Concentrations serum levels of IgG, IgA, IgM were assessed.

    Time frame: At Week 170

  31. DBTP and DBE Periods: Change From Baseline in Immunoglobulin (Ig) Levels

    Change from baseline serum levels of IgG, IgA, IgM were assessed.

    Time frame: Baseline up to 170 weeks

07

Results

Posted Jan 14, 2025
Limitations and caveats
The Final Analysis represents the analysis of the cumulative data collected up to the Primary Analysis trigger and beyond through DBE up to the final database lock. Therefore, the endpoints were evaluated considering a time period from the start of DBTP to the end of the DBE Period.

Participant flow

Double-blind Treatment Period: 156 Weeks
Participant flow — Double-blind Treatment Period: 156 Weeks
MilestoneTeriflunomideEvobrutinib
Started583583
Completed409410
Not completed174173
Withdrew: Withdrawal by subject5952
Withdrew: Lack of efficacy1116
Withdrew: Other reasons1722
Withdrew: Adverse event6770
Withdrew: Protocol non-compliance98
Withdrew: Lost to follow-up113
Withdrew: Randomized, but not treated02
Double-blind Extension Period: 96 Weeks
Participant flow — Double-blind Extension Period: 96 Weeks
MilestoneTeriflunomideEvobrutinib
Started390389
Completed381377
Not completed912
Withdrew: Withdrawal by subject21
Withdrew: Lost to follow-up12
Withdrew: Adverse event11
Withdrew: Protocol non-compliance10
Withdrew: Other reasons48

Outcome measures

PrimaryDouble Blind Treatment Period (DBTP) and Double Blind Extension (DBE) Period: Annualized Relapse Rate (ARR)

The qualifying relapse is the occurrence of new or worsening neurological symptoms attributable to Multiple Sclerosis (MS) (for more than \[\>\] 24 hours, no fever, infection, injury, adverse events (AEs), and preceded by a stable or improving neurological state for more than or equal to \[\>=\] 30 days).

Time frame:
Baseline up to 170 weeks
Reported as:
Mean · relapses per year
Double Blind Treatment Period (DBTP) and Double Blind Extension (DBE) Period: Annualized Relapse Rate (ARR)
relapses per yearTeriflunomideEvobrutinib
Double Blind Treatment Period (DBTP) and Double Blind Extension (DBE) Period: Annualized Relapse Rate (ARR)0.11 (0.09 to 0.13)0.11 (0.09 to 0.13)
SecondaryDBTP and DBE Period: Percentage of Participants Without 12-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)

Disability progression was defined as increase in EDSS of greater than or equal to \[\>=\] 1 point from baseline EDSS score, if EDSS score at baseline is 5.0 or less and an increase of \>=0.5 point, if the baseline score is 5.5. Disability progression is considered sustained for 12 weeks when the initial increase in the EDSS is confirmed at a regularly scheduled visit at least 12 weeks after the initial documentation of neurological worsening. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). Kaplan-Meier method was used to estimate the percentage of participants without 12-week CDP.

Time frame:
Week 96 and Week 156 (combined DBTP and DBE periods)
Reported as:
Number · percentage of participants
DBTP and DBE Period: Percentage of Participants Without 12-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)
percentage of participantsTeriflunomideEvobrutinib
Week 9688.9 (85.7 to 91.4)91.8 (88.9 to 93.9)
Week 15682.3 (76.0 to 87.1)85.0 (77.8 to 90.0)
SecondaryDBTP and DBE Period: Percentage of Participants Without 24-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)

Disability progression was defined as increase in EDSS of greater than or equal to \[\>=\] 1 point from baseline EDSS score, if EDSS score at baseline is 5.0 or less and an increase of \>=0.5 point, if the baseline score is 5.5. Disability progression is considered sustained for 24 weeks when the initial increase in the EDSS is confirmed at a regularly scheduled visit at least 24 weeks after the initial documentation of neurological worsening. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). Kaplan-Meier method was used to estimate the percentage of participants without 24-week CDP.

Time frame:
Week 96 and Week 156 (combined DBTP and DBE periods)
Reported as:
Number · percentage of participants
DBTP and DBE Period: Percentage of Participants Without 24-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)
percentage of participantsTeriflunomideEvobrutinib
Week 9691.6 (88.7 to 93.8)93.6 (91.0 to 95.5)
Week 15689.7 (86.5 to 92.2)90.9 (87.8 to 93.3)
SecondaryDBTP and DBE Period: Percentage of Participants With 24-Week Confirmed Disability Improvement (CDI) as Measured by Expanded Disability Status Scale (EDSS)

Disability improvement was defined as a reduction of 1 point from Baseline EDSS score when the Baseline score is \>= 2 and less than or equal to \[\<=\] 6 and a reduction of 0.5 point from Baseline EDSS score when the Baseline score is \>= 6.5 and \<= 9.5. Disability improvement is considered sustained when the initial reduction in the EDSS score is confirmed at a regularly scheduled visit at least 24 weeks after the initial reduction. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). Kaplan-Meier method was used to estimate the percentage of participants with 12-week CDI.

Time frame:
Week 96 and Week 156 (combined DBTP and DBE periods)
Reported as:
Number · percentage of participants
DBTP and DBE Period: Percentage of Participants With 24-Week Confirmed Disability Improvement (CDI) as Measured by Expanded Disability Status Scale (EDSS)
percentage of participantsTeriflunomideEvobrutinib
Week 9611.4 (8.6 to 15.0)7.6 (5.4 to 10.7)
Week 15612.5 (9.5 to 16.4)8.4 (6.0 to 11.6)
SecondaryDBTP and DBE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) Score at Week 48, Week 96, Week 120, Week 144 and Week 156

Physical function was assessed with PROMISnq Short Form v2.0 - Physical Function - Multiple Sclerosis 15a (PROMISnq PF(MS) 15a). PROMISnq PF(MS) 15a assesses a participant's abilities and limitations with respect to everyday physical activities. Results are reported as a T-score. In the general population, T-scores have a mean of 50, standard deviation of 10, and range from 10 to 65. Higher T-scores represent higher physical function. Change from baseline in PROMIS PF score was analyzed using Mixed Effect Model for Repeated Measures (MMRM) to evaluate the result of the 2 periods (DBTP and DBE).

Time frame:
Baseline, Week 48, Week 96, Week 120, Week 144 and Week 156 (Combined DBTP and DBE periods)
Reported as:
Least squares mean · units on a scale
DBTP and DBE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) Score at Week 48, Week 96, Week 120, Week 144 and Week 156
units on a scaleTeriflunomideEvobrutinib
Week 480.25 (-0.22 to 0.72)0.31 (-0.16 to 0.78)
Week 96-0.31 (-0.88 to 0.26)-0.45 (-1.03 to 0.13)
Week 120-0.56 (-1.23 to 0.11)-0.19 (-0.86 to 0.48)
Week 144-0.38 (-1.12 to 0.35)-0.57 (-1.31 to 0.17)
Week 156NA (NA to NA)NA (NA to NA)
SecondaryDBTP and DBE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Score at Week 48, Week 96, Week 120, Week 144 and Week 156

PROMIS Fatigue score was assessed with PROMIS Short Form v1.0 - Fatigue - Multiple Sclerosis 8a (PROMIS Fatigue (MS) 8a). PROMIS Fatigue (MS) 8a assesses level of fatigue and its interference on daily activities. Results are reported as a T-score. In the general population, T-scores have a mean of 50, standard deviation of 10, and range from 33 to 85. Higher T-scores represent higher fatigue. Change from baseline in PROMIS fatigue score was analyzed using Mixed Effect Model for Repeated Measures (MMRM) to evaluate the result of the 2 periods (DBTP and DBE).

Time frame:
Baseline, Week 48, Week 96, Week 120, Week 144 and Week 156 ((combined DBTP and DBE periods)
Reported as:
Least squares mean · units on a scale
DBTP and DBE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Score at Week 48, Week 96, Week 120, Week 144 and Week 156
units on a scaleTeriflunomideEvobrutinib
Week 48-2.20 (-2.81 to -1.60)-2.59 (-3.19 to -1.98)
Week 96-2.17 (-2.85 to -1.49)-2.12 (-2.81 to -1.44)
Week 120-2.24 (-3.00 to -1.48)-2.59 (-3.35 to -1.83)
Week 144-2.41 (-3.35 to -1.48)-2.16 (-3.10 to -1.22)
Week 156-2.21 (-3.62 to -0.81)-2.34 (-3.83 to -0.86)
SecondaryDBTP and DBE Period: Total Number of T1 Gadolinium-positive (Gd+) Lesions

Analysis of Gadolinium-positive T1 lesions was done using magnetic resonance imaging (MRI) scans.

Time frame:
Baseline up to 170 weeks
Reported as:
Mean · lesions per scan
DBTP and DBE Period: Total Number of T1 Gadolinium-positive (Gd+) Lesions
lesions per scanTeriflunomideEvobrutinib
DBTP and DBE Period: Total Number of T1 Gadolinium-positive (Gd+) Lesions0.29 (0.24 to 0.34)0.51 (0.43 to 0.60)
SecondaryDBTP and DBE Period: New or Enlarging T2 Lesions Rate

Analysis of new or enlarging T2 lesions rate was done using magnetic resonance imaging (MRI) scans. Negative binomial model for lesion count (summed over scans) includes treatment and covariates based on randomization strata and baseline volume of T2 lesion (continuous), with offset equal to the log of the time in years between the last available MRI scan and the baseline scan.

Time frame:
Baseline up to 170 weeks
Reported as:
Mean · lesions per year
DBTP and DBE Period: New or Enlarging T2 Lesions Rate
lesions per yearTeriflunomideEvobrutinib
DBTP and DBE Period: New or Enlarging T2 Lesions Rate6.88 (6.01 to 7.87)6.17 (5.38 to 7.07)
SecondaryDBTP Period: Neurofilament Light Chain (NfL) Concentration at Week 12

NfL is a biomarker of neuro-axonal damage whose concentration was assessed in blood at Week 12.

Time frame:
Week 12
Reported as:
Geometric mean · nanogram per liter (ng/L)
DBTP Period: Neurofilament Light Chain (NfL) Concentration at Week 12
nanogram per liter (ng/L)TeriflunomideEvobrutinib
DBTP Period: Neurofilament Light Chain (NfL) Concentration at Week 1213.09 (12.69 to 13.50)12.51 (12.13 to 12.90)
SecondaryDBTP and DBE Periods: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESIs)

Adverse event (AE): Any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the study drug. Serious AE: an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs: those AEs with an onset date on or after the date of first study intervention administration, or AEs present prior to any study intervention administration but exacerbating after. TEAEs included both Serious TEAEs and non-serious TEAEs. AESIs included liver AEs (possible drug-induced, non-infectious, non-alcoholic, and immune-mediated), infections (serious and opportunistic infections), lipase and amylase elevation, and seizure.

Time frame:
Baseline up to 170 weeks
Reported as:
Count of participants · Participants
DBTP and DBE Periods: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESIs)
ParticipantsTeriflunomideEvobrutinib
Participants with TEAEs524508
Participants with AESIs144135
SecondaryDBTP and DBE Periods: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity

Severity of adverse events (AE) were assessed by the investigator per the National Cancer Institute- Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0. Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death. Number of participants with Grades 1, 2, 3, 4 and 5 were reported.

Time frame:
Baseline up to 170 weeks
Reported as:
Count of participants · Participants
DBTP and DBE Periods: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity
ParticipantsTeriflunomideEvobrutinib
Participants with Grade 14159
Participants with Grade 2389351
Participants with Grade 38792
Participants with Grade 476
Participants with Grade 500
SecondaryDBTP and DBE Periods: Change From Baseline in Vital Signs: Diastolic Blood Pressure and Systolic Blood Pressure

Diastolic blood pressure and systolic blood pressure were measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: diastolic blood pressure and systolic blood pressure from baseline up to 170 weeks were reported.

Time frame:
Baseline up to 170 weeks
Reported as:
Mean · millimeter of mercury (mmHg)
DBTP and DBE Periods: Change From Baseline in Vital Signs: Diastolic Blood Pressure and Systolic Blood Pressure
millimeter of mercury (mmHg)TeriflunomideEvobrutinib
Systolic Blood Pressure2.4 ± 11.01.0 ± 11.50
Diastolic Blood Pressure1.4 ± 8.73-0.5 ± 8.38
SecondaryDBTP and DBE Periods: Change From Baseline in Vital Signs: Pulse Rate

Pulse rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: pulse rate from baseline up to 170 weeks was reported.

Time frame:
Baseline up to 170 weeks
Reported as:
Mean · beats per minute
DBTP and DBE Periods: Change From Baseline in Vital Signs: Pulse Rate
beats per minuteTeriflunomideEvobrutinib
DBTP and DBE Periods: Change From Baseline in Vital Signs: Pulse Rate2.2 ± 10.193.0 ± 10.15
SecondaryDBTP and DBE Periods: Change From Baseline in Vital Signs: Respiratory Rate

Respiratory rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: respiratory rate from baseline up to 170 weeks was reported.

Time frame:
Baseline up to 170 weeks
Reported as:
Mean · breaths per minute
DBTP and DBE Periods: Change From Baseline in Vital Signs: Respiratory Rate
breaths per minuteTeriflunomideEvobrutinib
DBTP and DBE Periods: Change From Baseline in Vital Signs: Respiratory Rate-0.3 ± 1.75-0.5 ± 1.87
SecondaryDBTP and DBE Periods: Change From Baseline in Vital Signs: Weight

Changes in vital signs: weight from baseline up to 170 weeks was reported.

Time frame:
Baseline up to 170 weeks
Reported as:
Mean · kilograms (kg)
DBTP and DBE Periods: Change From Baseline in Vital Signs: Weight
kilograms (kg)TeriflunomideEvobrutinib
DBTP and DBE Periods: Change From Baseline in Vital Signs: Weight-0.51 ± 5.4471.06 ± 5.310
SecondaryDBTP and DBE Periods: Change From Baseline in Vital Signs: Temperature

Temperature was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: Temperature from baseline up to 170 weeks was reported.

Time frame:
Baseline up to 170 weeks
Reported as:
Mean · degree Celsius
DBTP and DBE Periods: Change From Baseline in Vital Signs: Temperature
degree CelsiusTeriflunomideEvobrutinib
DBTP and DBE Periods: Change From Baseline in Vital Signs: Temperature-0.02 ± 0.340-0.03 ± 0.350
SecondaryDBTP and DBE Periods: Change From Baseline in Electrocardiograms (ECGs): Heart Rate

Heart rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: heart rate from baseline up to 170 weeks was reported.

Time frame:
Baseline up to 170 weeks
Reported as:
Mean · beats per minute
DBTP and DBE Periods: Change From Baseline in Electrocardiograms (ECGs): Heart Rate
beats per minuteTeriflunomideEvobrutinib
DBTP and DBE Periods: Change From Baseline in Electrocardiograms (ECGs): Heart Rate-0.1 ± 10.362.6 ± 10.20
SecondaryDBTP and DBE Periods: Change From Baseline in Electrocardiograms (ECGs): QT Interval - Fridericia's Correction Formula, PR Interval and QRS Duration

QT Interval - Fridericia's Correction Formula, PR Interval and QRS Duration was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: QT Interval - Fridericia's Correction Formula, PR Interval and QRS Duration from baseline up to 170 weeks were reported.

Time frame:
Baseline up to 170 weeks
Reported as:
Mean · milliseconds (msec)
DBTP and DBE Periods: Change From Baseline in Electrocardiograms (ECGs): QT Interval - Fridericia's Correction Formula, PR Interval and QRS Duration
milliseconds (msec)TeriflunomideEvobrutinib
QT Interval - Fridericia's Correction Formula-2.14 ± 16.459-0.07 ± 14.935
PR Interval-4.2 ± 16.82-3.1 ± 14.51
QRS Duration-2.8 ± 6.77-1.1 ± 8.94
SecondaryDBTP and DBE Periods: Change From Baseline in Hematology Parameter: Hemoglobin and Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameters: erythrocytes mean corpuscular HGB concentration and hemoglobin. Changes in hematology parameters: erythrocytes mean corpuscular HGB concentration and hemoglobin from baseline up to 170 weeks were reported.

Time frame:
Baseline up to 170 weeks
Reported as:
Mean · gram per liter (g/L)
DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Hemoglobin and Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration
gram per liter (g/L)TeriflunomideEvobrutinib
Erythrocytes Mean Corpuscular HGB Concentration0.0 ± 11.07-1.9 ± 12.42
Hemoglobin-3.4 ± 11.40-3.4 ± 11.43
SecondaryDBTP and DBE Periods: Change From Baseline in Hematology Parameter: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes and Reticulocytes

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameters: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes and Reticulocytes. Changes in hematology parameters: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes and Reticulocytes from baseline up to 170 weeks were reported.

Time frame:
Baseline up to 170 weeks
Reported as:
Mean · 10^9 cells per liter
DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes and Reticulocytes
10^9 cells per literTeriflunomideEvobrutinib
Platelets-8.4 ± 48.389.8 ± 52.24
Leukocytes-0.39 ± 1.9540.24 ± 1.883
Neutrophils-0.471 ± 1.75500.156 ± 1.7796
Eosinophils0.0198 ± 0.148090.0238 ± 0.14945
Basophils-0.0081 ± 0.03882-0.0042 ± 0.03902
Monocytes0.0797 ± 0.197100.0772 ± 0.20715
Lymphocytes-0.0241 ± 0.575640.0311 ± 0.57810
Reticulocytes2.001 ± 23.3886-0.841 ± 20.2200
SecondaryDBTP and DBE Periods: Change From Baseline in Hematology Parameters: Hematocrit

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Hematocrit. Changes in hematology parameter: Hematocrit from baseline up to 170 weeks was reported.

Time frame:
Baseline up to 170 weeks
Reported as:
Mean · percentage of cells
DBTP and DBE Periods: Change From Baseline in Hematology Parameters: Hematocrit
percentage of cellsTeriflunomideEvobrutinib
DBTP and DBE Periods: Change From Baseline in Hematology Parameters: Hematocrit-0.0107 ± 0.03199-0.0085 ± 0.03311
SecondaryDBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin. Changes in hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin from baseline up to 170 weeks was reported.

Time frame:
Baseline up to 170 weeks
Reported as:
Mean · picogram
DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
picogramTeriflunomideEvobrutinib
DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin-0.44 ± 1.603-0.93 ± 1.941
SecondaryDBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Erythrocytes Mean Corpuscular Volume. Changes in hematology parameter: Erythrocytes Mean Corpuscular Volume from baseline up to 170 weeks was reported.

Time frame:
Baseline up to 170 weeks
Reported as:
Mean · femtoliters
DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume
femtolitersTeriflunomideEvobrutinib
DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume-1.48 ± 4.150-2.53 ± 5.217
SecondaryDBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Bilirubin and Creatinine

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Bilirubin and Creatinine. Changes in biochemistry parameters: Bilirubin and Creatinine from baseline up to 170 weeks were reported.

Time frame:
Baseline up to 170 weeks
Reported as:
Mean · micromoles per liter (mcmol/L)
DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Bilirubin and Creatinine
micromoles per liter (mcmol/L)TeriflunomideEvobrutinib
Bilirubin-0.02 ± 4.6490.33 ± 4.212
Creatinine1.6 ± 8.932.4 ± 12.06
SecondaryDBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase. Changes in biochemistry parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase from baseline up to 170 weeks were reported.

Time frame:
Baseline up to 170 weeks
Reported as:
Mean · units per liter (U/L)
DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase
units per liter (U/L)TeriflunomideEvobrutinib
Aspartate Aminotransferase2.64 ± 15.3651.74 ± 13.219
Alanine Aminotransferase4.40 ± 33.8782.75 ± 32.018
Alkaline Phosphatase2.32 ± 15.8756.69 ± 15.659
Amylase1.3 ± 14.422.1 ± 15.91
Lipase-0.3 ± 18.352.3 ± 17.26
Gamma Glutamyl Transferase3.71 ± 26.0841.98 ± 20.207
Lactate Dehydrogenase7.08 ± 27.049-5.41 ± 27.637
SecondaryDBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Sodium, Potassium, Calcium, Magnesium, Glucose, Chloride, Urea Nitrogen, Phosphate, Bicarbonate and Corrected Calcium

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Sodium, Potassium, Calcium, Magnesium, Glucose, Chloride, Urea Nitrogen, Phosphate, Bicarbonate and Corrected Calcium. Changes in biochemistry parameters: Sodium, Potassium, Calcium, Magnesium, Glucose, Chloride, Urea Nitrogen, Phosphate, Bicarbonate and Corrected Calcium from baseline up to 170 weeks were reported.

Time frame:
Baseline up to 170 weeks
Reported as:
Mean · millimole per liter (mmol/L)
DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Sodium, Potassium, Calcium, Magnesium, Glucose, Chloride, Urea Nitrogen, Phosphate, Bicarbonate and Corrected Calcium
millimole per liter (mmol/L)TeriflunomideEvobrutinib
Sodium0.9286 ± 2.567960.7750 ± 3.21185
Potassium0.0405 ± 0.487500.0376 ± 0.44331
Calcium-0.006 ± 0.1197-0.008 ± 0.1121
Magnesium-0.002 ± 0.0656-0.006 ± 0.0667
Glucose0.09 ± 0.9490.16 ± 0.812
Chloride2.3 ± 3.302.1 ± 3.53
Urea Nitrogen0.126 ± 1.27590.122 ± 1.1651
Phosphate-0.047 ± 0.1944-0.024 ± 0.1799
Bicarbonate0.44 ± 2.5920.17 ± 2.980
Corrected Calcium0.0290 ± 0.104050.0292 ± 0.09775
SecondaryDBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Total Protein and Albumin

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Total Protein and Albumin. Changes in biochemistry parameters: Total Protein and Albumin from baseline up to 170 weeks were reported.

Time frame:
Baseline up to 170 weeks
Reported as:
Mean · gram per liter (g/L)
DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Total Protein and Albumin
gram per liter (g/L)TeriflunomideEvobrutinib
Total protein-1.31 ± 4.905-0.59 ± 4.998
Albumin-1.75 ± 3.497-1.83 ± 3.287
SecondaryDBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Glomerular Filtration Rate

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameter: Glomerular Filtration Rate. Changes in biochemistry parameter: Glomerular Filtration Rate from baseline up to 170 weeks were reported. The Glomerular Filtration Rate was measured as milliliter per minute per 1.73 square meter (mL/min/1.73m\^2).

Time frame:
Baseline up to 170 weeks
Reported as:
Mean · mL/min/1.73m^2
DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Glomerular Filtration Rate
mL/min/1.73m^2TeriflunomideEvobrutinib
DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Glomerular Filtration Rate-4.7 ± 13.41-5.7 ± 13.81
SecondaryDBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Potential of Hydrogen (pH) of Urine

Urine samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the urinalyses parameter: pH. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Changes in urinalyses parameter: pH from baseline up to 170 weeks was reported.

Time frame:
Baseline up to 170 weeks
Reported as:
Mean · pH
DBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Potential of Hydrogen (pH) of Urine
pHTeriflunomideEvobrutinib
DBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Potential of Hydrogen (pH) of Urine-0.03 ± 0.936-0.04 ± 0.973
SecondaryDBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Specific Gravity of Urine

Urine samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the urinalyses parameter: Specific Gravity of Urine. Changes in urinalyses parameter: Specific Gravity of Urine from baseline up to 170 weeks was reported.

Time frame:
Baseline up to 170 weeks
Reported as:
Mean · Kilogram per cubic meter
DBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Specific Gravity of Urine
Kilogram per cubic meterTeriflunomideEvobrutinib
DBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Specific Gravity of Urine-0.0015 ± 0.04460-0.0017 ± 0.03748
SecondaryDBTP and DBE Periods: Absolute Concentrations of Immunoglobulin (Ig) Levels

Absolute Concentrations serum levels of IgG, IgA, IgM were assessed.

Time frame:
At Week 170
Reported as:
Mean · gram per liter (g/L)
DBTP and DBE Periods: Absolute Concentrations of Immunoglobulin (Ig) Levels
gram per liter (g/L)TeriflunomideEvobrutinib
IgA1.899 ± 0.77872.581 ± 1.1201
IgG10.082 ± 2.155110.990 ± 2.4844
IgM1.251 ± 0.64451.196 ± 0.6151
SecondaryDBTP and DBE Periods: Change From Baseline in Immunoglobulin (Ig) Levels

Change from baseline serum levels of IgG, IgA, IgM were assessed.

Time frame:
Baseline up to 170 weeks
Reported as:
Mean · gram per liter (g/L)
DBTP and DBE Periods: Change From Baseline in Immunoglobulin (Ig) Levels
gram per liter (g/L)TeriflunomideEvobrutinib
IgA-0.203 ± 0.57040.500 ± 0.7197
IgG-0.645 ± 1.61880.146 ± 1.8712
IgM-0.167 ± 0.5094-0.175 ± 0.3888

Adverse events

Collected over Baseline up to 170 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Teriflunomide0/583 (0%)37/583 (6.3%)455/583 (78%)
Evobrutinib0/581 (0%)51/581 (8.8%)409/581 (70.4%)
Most frequent serious events
Showing 10 of 85
Most frequent serious events
EventTeriflunomideEvobrutinib
Alanine aminotransferase increasedInvestigations3/5837/581
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/5834/581
Aspartate aminotransferase increasedInvestigations2/5833/581
Multiple sclerosis relapseNervous system disorders1/5833/581
AppendicitisInfections and infestations1/5832/581
COVID-19Infections and infestations1/5832/581
COVID-19 pneumoniaInfections and infestations2/5832/581
Urinary tract infectionInfections and infestations0/5832/581
Lumbosacral radiculopathyNervous system disorders0/5832/581
Accidental overdoseInjury, poisoning and procedural complications2/5830/581
Most frequent other events
Showing 10 of 21
Most frequent other events
EventTeriflunomideEvobrutinib
Alanine aminotransferase increasedInvestigations126/58399/581
COVID-19Infections and infestations121/583105/581
HeadacheNervous system disorders103/58396/581
Neutrophil count decreasedInvestigations92/58340/581
AlopeciaSkin and subcutaneous tissue disorders84/58335/581
Aspartate aminotransferase increasedInvestigations80/58361/581
NasopharyngitisInfections and infestations67/58358/581
White blood cell count decreasedInvestigations63/58323/581
Back painMusculoskeletal and connective tissue disorders61/58349/581
Upper respiratory tract infectionInfections and infestations45/58355/581

Baseline characteristics

Full Analysis Set (FAS) included all participants who were randomized to study treatment.

Age, Continuous
Age, Continuous(Years)TeriflunomideEvobrutinibTotal
Mean37 ± 9.536 ± 9.137 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)TeriflunomideEvobrutinibTotal
Female370413783
Male213170383
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TeriflunomideEvobrutinibTotal
Ethnicity-Hispanic or Latino305181
Ethnicity-Not Hispanic or Latino5535311084
Ethnicity-Unknown or Not Reported011
Race-American Indian or Alaska Native112
Race-Asian171532
Race-Black or African American448
Race-Multiple729
Race-Native Hawaiian or Other Pacific Islander011
Race-Other123
Race-Unknown or Not Reported224
Race-White5515561107
08

Study locations

278 sites
  • Research Site 752
    Cullman, Alabama 35058, United States
  • Research Site 741
    Scottsdale, Arizona 85258, United States
  • Research Site 704
    Tucson, Arizona 85710, United States
  • Research Site 751
    Hanford, California 93230, United States
  • Research Site 737
    West Hollywood, California 90048, United States
  • Research Site 759
    Colorado Springs, Colorado 80907, United States
  • Research Site 725
    Fort Collins, Colorado 80528, United States
  • Research Site 746
    Altamonte Springs, Florida 32714, United States
  • Research Site 718
    Jacksonville, Florida 32209, United States
  • Research Site 702
    Naples, Florida 34105, United States
  • Research Site 740
    Orlando, Florida 32806, United States
  • Research Site 726
    Port Charlotte, Florida 33952, United States
  • Research Site 719
    Sarasota, Florida 34243, United States
  • Research Site 743
    Tampa, Florida 33612, United States
  • Research Site 707
    Tampa, Florida 33634, United States
  • Research Site 732
    Vero Beach, Florida 32960, United States
  • Research Site 705
    Weeki Wachee, Florida 34607, United States
  • Research Site 753
    West Palm Beach, Florida 33407, United States
  • Research Site 742
    Honolulu, Hawaii 96817, United States
  • Research Site 715
    Evanston, Illinois 60201, United States
  • Research Site 714
    Fort Wayne, Indiana 46804, United States
  • Research Site 744
    Lafayette, Indiana 47904, United States
  • Research Site 717
    Overland Park, Kansas 66212, United States
  • Research Site 735
    Nicholasville, Kentucky 40356, United States
  • Research Site 706
    Scarborough, Maine 04074, United States
  • Research Site 738
    Detroit, Michigan 48202, United States
  • Research Site 723
    Saint Louis, Missouri 63128, United States
  • Research Site 724
    Amherst, New York 14226, United States
  • Research Site 736
    Asheville, North Carolina 28006, United States
  • Research Site 712
    Chapel Hill, North Carolina 27599, United States
  • Research Site 730
    Raleigh, North Carolina 27607, United States
  • Research Site 728
    Winston-Salem, North Carolina 27157, United States
  • Research Site 711
    Canton, Ohio 44735, United States
  • Research Site 757
    Columbus, Ohio 43214, United States
  • Research Site 734
    Dayton, Ohio 45459, United States
  • Research Site 748
    Philadelphia, Pennsylvania 19107, United States
  • Research Site 703
    San Antonio, Texas 78258, United States
  • Research Site 721
    Norfolk, Virginia 23502, United States
  • Research Site 144
    Gomel, Belarus
  • Research Site 143
    Grodno, Belarus
  • Research Site 142
    Minsk, Belarus
  • Research Site 141
    Vitebsk, Belarus
  • Research Site 145
    Vitebsk, Belarus
  • Research Site 603
    Belo Horizonte, Brazil
  • Research Site 599
    Curitiba, Brazil
  • Research Site 604
    Goiânia, Brazil
  • Research Site 600
    Joinville, Brazil
  • Research Site 614
    Passo Fundo, Brazil
  • Research Site 591
    Porto Alegre, Brazil
  • Research Site 594
    Porto Alegre, Brazil
  • Research Site 596
    Porto Alegre, Brazil
  • Research Site 609
    Vitória, Brazil
  • Research Site 155
    Blagoevgrad, Bulgaria
  • Research Site 156
    Dupnitsa, Bulgaria
  • Research Site 157
    Pleven, Bulgaria
  • Research Site 801
    Pleven, Bulgaria
  • Research Site 804
    Pleven, Bulgaria
  • Research Site 805
    Plovdiv, Bulgaria
  • Research Site 151
    Sofia, Bulgaria
  • Research Site 152
    Sofia, Bulgaria
  • Research Site 153
    Sofia, Bulgaria
  • Research Site 158
    Sofia, Bulgaria
  • Research Site 159
    Sofia, Bulgaria
  • Research Site 160
    Sofia, Bulgaria
  • Research Site 802
    Sofia, Bulgaria
  • Research Site 803
    Sofia, Bulgaria
  • Research Site 808
    Sofia, Bulgaria
  • Research Site 154
    Veliko Tarnovo, Bulgaria
  • Research Site 106
    Burnaby, Canada
  • Research Site 107
    London, Canada
  • Research Site 105
    Montreal, Canada
  • Research Site 101
    Ottawa, Canada
  • Research Site 455
    Bordeaux Cedex, France
  • Research Site 459
    Brest cedex 2, France
  • Reserach Site 451
    Clermont Ferrand Cedex, France
  • Research Site 458
    Limoges cedex, France
  • Research Site 456
    Nimes, France
  • Research Site 453
    Paris, France
  • Research Site 457
    Pringy cedex, France
  • Research Site 452
    Strasbourg cedex, France
  • Research Site 454
    Tours cedex 9, France
  • Research Site 172
    Augsburg, Germany
  • Research Site 177
    Berlin, Germany
  • Research Site 180
    Berlin, Germany
  • Research Site 178
    Bonn, Germany
  • Research Site 184
    Dresden, Germany
  • Research Site 174
    Hamburg, Germany
  • Research Site 182
    Heidelberg, Germany
  • Research Site 179
    Koeln, Germany
  • Research Site 181
    Leipzig, Germany
  • Research Site 173
    Mainz, Germany
  • Research Site 176
    Minden, Germany
  • Research Site 171
    Regensburg, Germany
  • Research Site 183
    Rostock, Germany
  • Research Site 175
    Tuebingen, Germany
  • Research Site 194
    Athens, Greece
  • Research Site 196
    Athens, Greece
  • Research Site 197
    Athens, Greece
  • Research Site 201
    Athens, Greece
  • Research Site 202
    Athens, Greece

Showing the first 100 of 278 sites across 32 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials. Lancet Neurol. 2024 Nov;23(11):1119-1132. doi: 10.1016/S1474-4422(24)00328-4. Epub 2024 Sep 19. PubMed 39307151 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Within six months after the approval of a new product or a new indication for an approved product in both the United States and the European Union

Access criteria: Qualified scientific and medical researchers can request the data. Such requests must be submitted in writing to the company's portal and will be internally reviewed regarding criteria for researchers' qualification and legitimacy of the research proposal.

Data sharing details ↗ · bit.ly

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Oct 2023, 39 months.

Results were first posted in Jan 2025, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2020
First posted
Apr 8, 2020
StartActual
Jul 2, 2020
Primary completionActual
Oct 2, 2023
CompletionActual
Mar 19, 2024
Results first posted
Jan 14, 2025
Last update
Mar 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04338061
Responsible party
Sponsor
First posted
Apr 8, 2020
Start date
Jul 2, 2020
Primary completion
Oct 2, 2023
Completion
Mar 19, 2024
Results posted
Jan 14, 2025
Last update
Mar 21, 2025

Study contacts

Medical Responsible
study director · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evobrutinib

Start the discussion